Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4151266 | 0.94 | NFKB1 (0.39) | NFKB1NFKB2RELASMN1; SMN2HDAC6 | |
| SCHEMBL32687916 | 0.84 | NFKB1 (0.35) | NFKB1NFKB2RELASMN1; SMN2MEN1 | |
| SCHEMBL1771498 | 0.84 | NFKB1 (0.36) | NFKB1NFKB2RELASMN1; SMN2MEN1 | |
| SCHEMBL16067775 | 0.83 | NPSR1 (0.33) | — | |
| SCHEMBL13435746 | 0.81 | NFKB1 (0.40) | NFKB1NFKB2RELASMN1; SMN2MEN1 | |
| SCHEMBL31252248 | 0.80 | SMN1; SMN2 (0.35) | NFKB1NFKB2RELASMN1; SMN2MEN1 | |
| SCHEMBL7019111 | 0.80 | NPSR1 (0.37) | — | |
| SCHEMBL31252257 | 0.79 | AKT1 (0.37) | NFKB1NFKB2RELASMN1; SMN2MEN1 | |
| SCHEMBL1770349 | 0.79 | CTSD (0.31) | CTSDCTSLCTSBCTSS | |
| SCHEMBL15116608 | 0.79 | CTSD (0.31) | CTSDCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4525873-A1 | FLT3 COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | Biomea Fusion, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2023225005-A1 | FLT3 COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | BIOMEA FUSION, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225005-A1 | FLT3 COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | BIOMEA FUSION, INC. (US) | 2023-11-23 | — | — | WO | disclosed |